Belinda B. Garana

The paper develops EXACT, a framework combining ex vivo drug screening with transcriptomic analysis to identify effective drug combinations for rare cancers, finding a MEK and HDAC inhibitor combination shows enhanced activity.

This study integrates multi-omics data from MPNSTs to identify drug targets based on chromosome 8q status, suggesting PLK1 and EGFR inhibitors could be effective in different subtypes.

This paper introduces DMEA, a method that improves drug repurposing by grouping drugs with shared mechanisms of action, enhancing prioritization and reducing off-target effects.